You are here

Heart Failure

 

New research from Newcastle University found the use of left ventricular assist devices (LVADs) combined with medication can fully restore heart function in patients with end stage heart failure, a major breakthrough for heart failure patients who haven’t received a transplant and are running out of options.

At six months, patients with advanced heart failure who were implanted with the HeartMate 3 left ventricular assist system were less likely to have hemocompatibility- related clinical adverse events (HRAEs) compared with those who received the HeartMate II device, according to a randomized trial.

New research from the University of Gothenburg in Sweden has suggested that bigger women, classified as those who are taller than average and are overweight, could be at a greater risk of atrial fibrillation (AFib).

Researchers from Case Western Reserve University have found a new target for drug developers looking for ways to improve cardiac function in heart failure patients.

A person's unique genetic makeup may mean greater chances of certain harmful conditions, but other times, one's genes can actually be a defense against negative health outcomes. New research from Washington University’s School of Medicine in St. Louis explores how this concept could help develop therapies intended to reduce the risk of heart attack.

 

Recent Headlines

FDA designates Medtronic’s recall of HVAD system controllers, DC adapters as class I recall

The FDA determined that Medtronic’s voluntary recall of its HVAD system controllers and DC adapters was a class I recall, according to a Medtronic news release on April 18.

Endotronix hires three to join its management team

Endotronix recently announced it had recently hired several executives to join its management team.

LVAD, medications can fully restore function in heart failure patients

New research from Newcastle University found the use of left ventricular assist devices (LVADs) combined with medication can fully restore heart function in patients with end stage heart failure, a major breakthrough for heart failure patients who haven’t received a transplant and are running out of options.

Advanced heart failure patients have superior outcomes with HeartMate 3 device

At six months, patients with advanced heart failure who were implanted with the HeartMate 3 left ventricular assist system were less likely to have hemocompatibility- related clinical adverse events (HRAEs) compared with those who received the HeartMate II device, according to a randomized trial.

Taller, overweight women could be at increased risk for AFib

New research from the University of Gothenburg in Sweden has suggested that bigger women, classified as those who are taller than average and are overweight, could be at a greater risk of atrial fibrillation (AFib).

Protein shown to improve cardiac function could be used for heart failure drugs

Researchers from Case Western Reserve University have found a new target for drug developers looking for ways to improve cardiac function in heart failure patients.

Subclinical hypothyroidism associated with adverse cardiac outcomes

New research from the University of Pennsylvania shows that patients with severe heart failure have higher levels of thyroid hormones, which can be responsible for causing atrial fibrillation.

Gene mutation could help develop drug to reduce heart attacks

A person's unique genetic makeup may mean greater chances of certain harmful conditions, but other times, one's genes can actually be a defense against negative health outcomes. New research from Washington University’s School of Medicine in St. Louis explores how this concept could help develop therapies intended to reduce the risk of heart attack.

Insomnia linked to increased risk of heart failure, stroke

New research from China has found insomnia can be a cause for an increased risk in having a heart attack or stroke, a finding that can help cardiologists better predict a patient’s risk for experiencing an adverse cardiac event.

Heart failure medication falls short of primary endpoint in phase 3 trial

Novartis announced that a phase 3 study evaluating the company’s investigational heart failure medication (serelaxin) did not meet its primary endpoint.

Pages